172 related articles for article (PubMed ID: 36601880)
81. KMT2C is a Potential Biomarker of Anti-PD-1 Treatment Response in Metastatic Melanoma.
Xie K; Peng Y; Zhong W; Liu X
Front Biosci (Landmark Ed); 2022 Mar; 27(3):103. PubMed ID: 35345335
[TBL] [Abstract][Full Text] [Related]
82. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.
Yoshimura K; Inoue Y; Tsuchiya K; Karayama M; Yamada H; Iwashita Y; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Lung Cancer; 2020 Mar; 141():21-31. PubMed ID: 31931443
[TBL] [Abstract][Full Text] [Related]
83. Molecular Characteristics of Lymphocyte-predominant Triple-negative Breast Cancer.
Sasaki R; Horimoto Y; Yanai Y; Kurisaki-Arakawa A; Arakawa A; Nakai K; Saito M; Saito T
Anticancer Res; 2021 Apr; 41(4):2133-2140. PubMed ID: 33813424
[TBL] [Abstract][Full Text] [Related]
84. Mismatch Repair Status of Gastric Cancer and Its Association with the Local and Systemic Immune Response.
Shin SJ; Kim SY; Choi YY; Son T; Cheong JH; Hyung WJ; Noh SH; Park CG; Kim HI
Oncologist; 2019 Sep; 24(9):e835-e844. PubMed ID: 30894409
[TBL] [Abstract][Full Text] [Related]
85. PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients.
Wang Y; Chen H; Jiao X; Wu L; Yang Y; Zhang J; Wu L; Liu C; Zhuo N; Li S; Gong J; Li J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Li J; Li Y; Lu Z; Zhang H; Shen L
Cancer Immunol Immunother; 2022 Jan; 71(1):111-120. PubMed ID: 34028566
[TBL] [Abstract][Full Text] [Related]
86. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer.
Lin A; Zhang J; Luo P
Front Immunol; 2020; 11():2039. PubMed ID: 32903444
[TBL] [Abstract][Full Text] [Related]
87. Intratumoral infiltrating lymphocytes correlate with improved survival in colorectal cancer patients: Independent of oncogenetic features.
Nazemalhosseini-Mojarad E; Mohammadpour S; Torshizi Esafahani A; Gharib E; Larki P; Moradi A; Amin Porhoseingholi M; Asadzade Aghdaei H; Kuppen PJK; Zali MR
J Cell Physiol; 2019 Apr; 234(4):4768-4777. PubMed ID: 30370522
[TBL] [Abstract][Full Text] [Related]
88. Tumor mutational burden in colorectal cancer: Implications for treatment.
Marques A; Cavaco P; Torre C; Sepodes B; Rocha J
Crit Rev Oncol Hematol; 2024 May; 197():104342. PubMed ID: 38614266
[TBL] [Abstract][Full Text] [Related]
89. TTN/OBSCN 'Double-Hit' predicts favourable prognosis, 'immune-hot' subtype and potentially better immunotherapeutic efficacy in colorectal cancer.
Liu Z; Wang L; Guo C; Liu L; Jiao D; Sun Z; Wu K; Zhao Y; Han X
J Cell Mol Med; 2021 Apr; 25(7):3239-3251. PubMed ID: 33624434
[TBL] [Abstract][Full Text] [Related]
90. The Role of SPEN Mutations as Predictive Biomarkers for Immunotherapy Response in Colorectal Cancer: Insights from a Retrospective Cohort Analysis.
Dong Y; Ye S; Li H; Li J; Liu R; Zhu Y
J Pers Med; 2024 Jan; 14(2):. PubMed ID: 38392565
[TBL] [Abstract][Full Text] [Related]
91. The epigenetic modifier lysine methyltransferase 2C is frequently mutated in gastric remnant carcinoma.
Sun B; Chen H; Lao J; Tan C; Zhang Y; Shao Z; Xu D
J Pathol Clin Res; 2023 Sep; 9(5):409-422. PubMed ID: 37395342
[TBL] [Abstract][Full Text] [Related]
92. Immune checkpoint inhibitors in colorectal cancer: limitation and challenges.
Yan S; Wang W; Feng Z; Xue J; Liang W; Wu X; Tan Z; Zhang X; Zhang S; Li X; Zhang C
Front Immunol; 2024; 15():1403533. PubMed ID: 38919624
[TBL] [Abstract][Full Text] [Related]
93. Predictive biomarkers of colon cancer immunotherapy: Present and future.
Hou W; Yi C; Zhu H
Front Immunol; 2022; 13():1032314. PubMed ID: 36483562
[TBL] [Abstract][Full Text] [Related]
94. Somatic mutations in DCC are associated with genomic instability and favourable outcomes in melanoma patients treated with immune checkpoint inhibitors.
Li Y; Wang Q; Chen Y; Zhao L
Br J Cancer; 2022 Nov; 127(8):1411-1423. PubMed ID: 35871235
[TBL] [Abstract][Full Text] [Related]
95.
Huang K; Ding S; Chen K; Guo C; Wu M; Zhang R; Wang L; Fu Y; Xiao J; Liu X
Am J Cancer Res; 2023; 13(11):5549-5558. PubMed ID: 38058823
[No Abstract] [Full Text] [Related]
96. A20 promotes colorectal cancer immune evasion by upregulating STC1 expression to block "eat-me" signal.
Luo M; Wang X; Wu S; Yang C; Su Q; Huang L; Fu K; An S; Xie F; To KKW; Wang F; Fu L
Signal Transduct Target Ther; 2023 Aug; 8(1):312. PubMed ID: 37607946
[TBL] [Abstract][Full Text] [Related]
97. Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer.
Bergom HE; Sena LA; Day A; Miller B; Miller CD; Lozada JR; Zorko N; Wang J; Shenderov E; Lobo FP; Caramella-Pereira F; Marchionni L; Drake CG; Lotan T; De Marzo AM; Hwang J; Antonarakis ES
NPJ Genom Med; 2024 Jan; 9(1):7. PubMed ID: 38253539
[TBL] [Abstract][Full Text] [Related]
98. Deep computational phenotyping of genomic variants impacting the SET domain of KMT2C reveal molecular mechanisms for their dysfunction.
Jorge SD; Chi YI; Mazaba JL; Haque N; Wagenknecht J; Smith BC; Volkman BF; Mathison AJ; Lomberk G; Zimmermann MT; Urrutia R
Front Genet; 2023; 14():1291307. PubMed ID: 38090150
[No Abstract] [Full Text] [Related]
99.
Meng XY
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37277194
[No Abstract] [Full Text] [Related]
100. Immune check point inhibition in Colorectal Cancer: Current challenges and concerns.
Zubair R; Mughal S; Imran L
J Pak Med Assoc; 2023 Apr; 73(4):959. PubMed ID: 37052037
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
